This was drawn as the starting point to jointly promote the transformation and application of successful scientific research projects, with the goal of establishing a medical and health demonstration area to drive world-class research and innovation.
CH Biomedical, an innovative R&D company incubated by the investment section of Baheal Pharmaceutical Group, announced that its new generation of fully magnetically levitated artificial heart was officially approved for marketing.
Qingdao Baheal Medical Inc. and Astellas Pharma China Inc. reached a deeper cooperation agreement on the promotion and operation of Astellas' drugs Betmiga® (mirabellum extended-release tablets), Vesicare® (solifenacin succinate tablets) and Harnal® (tamsulosin hydrochloride extended-release capsules) in mainland China.
On June 30, 2021, Qingdao Baheal Medical Inc. (refer ro “Baheal Medical”, Stock Code: 301015) landed on ChiNext Board of Shenzhen Stock Exchange. On the first day of listing, the stock of Baheal Medicine opened at RMB 35.10 per share, up 359.42%.